Home Hansoh Pharmaceutical's Ameile® Wins China Patent Gold Award for EGFR Inhibitor Innovation

Hansoh Pharmaceutical's Ameile® Wins China Patent Gold Award for EGFR Inhibitor Innovation

Jul 25, 2023 14:34 CST Updated 14:34
Hansoh Pharma

Pharmaceutical Research, Production, and Sales

Hansoh Pharma

Innovative Therapeutic Drug Developer

ShanghaiJuly 25, 2023/PR Newswire/ --Recently, the National Intellectual Property Administration issued the "Decision of the National Intellectual Property Administration on the Awarding of the 24th China Patent Awards." The invention patent "EGFR Inhibitors and Their Preparation and Application" (Patent No.: ZL 201580045311.2) for Hansoh Pharma's innovative drug Almela® (Aumolertinib Mesylate Tablets), a key subsidiary of Hansoh Pharmaceutical Group Company Limited, was awarded the Gold Medal of the 24th "China Patent Award." This marks the second time Hansoh Pharma has received this honor, following the award for the patent of Zequn® (Gemcitabine Hydrochloride for Injection).

Hansoh Pharma Wins China Patent Gold Award Twice, Marking the Powerful Momentum of Its Continuous Innovation Drive

Behind the continuous fruitful results of innovative R&D, there is Hansoh Pharma's forward-looking patent layout, systematic institutional construction, and high-intensity resource investment. The patent affairs team of Hansoh Pharma has formulated and implemented more than 20 intellectual property management systems, building a comprehensive and multi-level patent layout covering compounds, pharmaceutical crystal forms, drug formulations, intermediates, preparation processes, and medical uses, providing comprehensive and three-dimensional patent protection to maintain the competitive advantages of products in both domestic and international markets.

Hansoh Pharma has cumulatively won 2 Gold Awards, 1 Silver Award, and 6 Excellence Awards for Chinese Invention Patents, as well as 1 Gold Award for Jiangsu Province patents. It has been recognized by the China National Intellectual Property Administration as a "National Intellectual Property Demonstration Enterprise" for many years in a row. The "High-Value Patent Cultivation Demonstration Center" project led by the company was selected as a typical case by the China National Intellectual Property Administration in 2021 and promoted nationwide.